
Better Science Better Health

Putting MAPPs into Practice in Europe

Jeremy Haigh

Amgen

Delivering Innovation Beyond 2014

Science	<i>Where does it lead us?</i>
Collaboration	<i>Core competency for the future?</i>
Data	<i>Generation or analysis?</i>
Patients	<i>Focus of our attention?</i>

Legislative and Regulatory Pathways Aren't Keeping Pace with Scientific Innovation

Advances

- Genomics
- Biomarkers
- New statistical methods
- Dynamic tools for collecting real world data
- Effective risk management

Limitations

- Trials are slow, expensive and inflexible
- Regulatory framework rigid and burdensome
- Evaluation systems don't reflect the total net benefit of new therapies
- Incentives are inadequate

Removing Barriers; Enabling Collaboration Where Must We Focus First?

1. Enhance academic / industry partnerships
2. Invest in e-health records, biobanks, genetic databases and linkages between them
3. Harness 'real world' data to improve patient outcomes
4. Adopt innovative clinical trial designs
5. Modify evaluation frameworks
6. Establish coherent HTA processes
7. Promote flexible pricing

Public/private partnerships (e.g. IMI2) provide a neutral platform for multi-stakeholder collaboration